Next Article in Journal
Effect of Perioperative Lipid Status on Clinical Outcomes after Cardiac Surgery
Previous Article in Journal
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine
 
 
Review

Vaccines against COVID-19: Priority to mRNA-Based Formulations

Department of Dermatology, University Hospital of Zürich, Raemistrasse 100, 8091 Zürich, Switzerland
Academic Editor: Arnaldo Caruso
Cells 2021, 10(10), 2716; https://doi.org/10.3390/cells10102716
Received: 25 August 2021 / Revised: 5 October 2021 / Accepted: 8 October 2021 / Published: 11 October 2021
(This article belongs to the Special Issue Vaccines, Therapies and Research Based on Synthetic mRNA)
As of September 2021, twenty-one anti-COVID-19 vaccines have been approved in the world. Their utilization will expedite an end to the current pandemic. Besides the usual vaccine formats that include inactivated viruses (eight approved vaccines) and protein-based vaccines (four approved vaccines), three new formats have been validated: recombinant adenovirus (six approved vaccines), DNA (one approved vaccine), and messenger RNA (mRNA, two approved vaccines). The latter was the fastest (authorized in 2020 in the EU, the USA, and Switzerland). Most Western countries have reserved or use the protein vaccines, the adenovirus vaccines, and mRNA vaccines. I describe here the different vaccine formats in the context of COVID-19, detail the three formats that are chiefly reserved or used in Europe, Canada, and the USA, and discuss why the mRNA vaccines appear to be the superior format. View Full-Text
Keywords: mRNA; protein; adenovirus; SARS-CoV-2; vaccine; spike mRNA; protein; adenovirus; SARS-CoV-2; vaccine; spike
Show Figures

Figure 1

MDPI and ACS Style

Pascolo, S. Vaccines against COVID-19: Priority to mRNA-Based Formulations. Cells 2021, 10, 2716. https://doi.org/10.3390/cells10102716

AMA Style

Pascolo S. Vaccines against COVID-19: Priority to mRNA-Based Formulations. Cells. 2021; 10(10):2716. https://doi.org/10.3390/cells10102716

Chicago/Turabian Style

Pascolo, Steve. 2021. "Vaccines against COVID-19: Priority to mRNA-Based Formulations" Cells 10, no. 10: 2716. https://doi.org/10.3390/cells10102716

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop